Malaria Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2500
Buy Report View Sample

Published: September 30, 2022 Report Code: GDGMDHC22348IDB-ST

Select Item

Malaria Pipeline Drugs Market Overview

Malaria is a life-threatening blood disease caused by a parasite (Plasmodium) that is transmitted to humans by the Anopheles mosquito. People at increased risk of serious disease include young children and infants, travelers coming from areas with no malaria, and pregnant women and their unborn children.

The Malaria pipeline drugs market research report provides comprehensive information on the therapeutics under development for Malaria, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Malaria and features dormant and discontinued projects.

Malaria Pipeline Products Market Segmentation by Targets

The key targets in the Malaria pipeline drugs market are Plasmodium falciparum Circumsporozoite Protein, Plasmodium falciparum 25 kDa Ookinete Surface Antigen, Plasmodium falciparum Merozoite Surface Protein 1, P Type ATPase4, Beta Hematin, Dihydroorotate Dehydrogenase (Quinone) Mitochondrial, Heme Polymerase, Plasmodium falciparum Apical Membrane Antigen 1, Plasmodium falciparum Gametocyte Surface Protein P45/48, Plasmodium falciparum Reticulocyte Binding Protein Homologue 5, and others.

Malaria Pipeline drugs Market Analysis by Targets

Malaria Pipeline Products Market Analysis by Targets

For more target insights into the Malaria pipeline products market, download a free report sample

Malaria Pipeline Products Market Segmentation by Mechanisms of Action

The key mechanisms of action in the Malaria pipeline drugs market are P Type ATPase4 Inhibitor, Plasmodium falciparum Circumsporozoite Protein Inhibitor, Beta Hematin Inhibitor, Dihydroorotate Dehydrogenase (Quinone) Mitochondrial Inhibitor, Heme Polymerase Inhibitor, 16S Ribosomal RNA Inhibitor, Cytochrome bc1 Complex Inhibitor, Dihydrofolate Reductase Inhibitor, DNA Inhibitor, Histone Lysine N Methyltransferase EHMT2 Inhibitor, and others.

Malaria Pipeline drugs Market Analysis by Mechanisms of Action

Malaria Pipeline Products Market Analysis by Mechanisms of Action

For more mechanisms of action insights into the Malaria pipeline products market, download a free report sample

Malaria Pipeline Products Market Segmentation by Routes of Administration

The key routes of administration in the Malaria pipeline drugs market are oral, intramuscular, intravenous, subcutaneous, parenteral, intradermal, inhalational, nasal, and transdermal.

Malaria Pipeline drugs Market Analysis by Routes of Administration

Malaria Pipeline Products Market Analysis by Routes of Administration

For more routes of administration insights into the Malaria pipeline products market, download a free report sample

Malaria Pipeline Products Market Segmentation by Molecule Types

The key molecule types in the Malaria pipeline products market are small molecule, subunit vaccine, recombinant vector vaccine, vaccine, monoclonal antibody, live attenuated vaccine, mRNA vaccine, DNA vaccine, antisense oligonucleotide, antisense RNAi oligonucleotide, and others.

Malaria Pipeline Products Market Analysis by Molecule Types

Malaria Pipeline Products Market Analysis by Molecule TypesFor more molecule type insights into the Malaria pipeline products market, download a free report sample

Competitive Landscape

Some of the leading players in the Malaria pipeline products market are Eisai Co Ltd, GSK plc, Novartis AG, Sanaria Inc, Vac4All SAS, Zydus Lifesciences Ltd, Expres2ion Biotechnologies ApS, Ocean Biomedical Inc, Sanofi, and Alfasigma SpA.

Malaria Pipeline Products Market Analysis by Players

Malaria Pipeline Products Market Analysis by Players

To know more about the leading players in the Malaria pipeline products market, download a free report sample

Malaria Pipeline Products Market Report Overview

Key Targets Plasmodium falciparum Circumsporozoite Protein, Plasmodium falciparum 25 kDa Ookinete Surface Antigen, Plasmodium falciparum Merozoite Surface Protein 1, P Type ATPase4, Beta Hematin, Dihydroorotate Dehydrogenase (Quinone) Mitochondrial, Heme Polymerase, Plasmodium falciparum Apical Membrane Antigen 1, Plasmodium falciparum Gametocyte Surface Protein P45/48, Plasmodium falciparum Reticulocyte Binding Protein Homologue 5, and Others
Key Mechanisms of Action P Type ATPase4 Inhibitor, Plasmodium falciparum Circumsporozoite Protein Inhibitor, Beta Hematin Inhibitor, Dihydroorotate Dehydrogenase (Quinone) Mitochondrial Inhibitor, Heme Polymerase Inhibitor, 16S Ribosomal RNA Inhibitor, Cytochrome bc1 Complex Inhibitor, Dihydrofolate Reductase Inhibitor, DNA Inhibitor, Histone Lysine N Methyltransferase EHMT2 Inhibitor, and Others
Key Routes of Administration Oral, Intramuscular, Intravenous, Subcutaneous, Parenteral, Intradermal, Inhalational, Nasal, and Transdermal
Key Molecule Type Small Molecule, Subunit Vaccine, Recombinant Vector Vaccine, Vaccine, Monoclonal Antibody, Live Attenuated Vaccine, mRNA Vaccine, DNA Vaccine, Antisense Oligonucleotide, Antisense RNAi Oligonucleotide, and Others
Leading Players Eisai Co Ltd, GSK plc, Novartis AG, Sanaria Inc, Vac4All SAS, Zydus Lifesciences Ltd, Expres2ion Biotechnologies ApS, Ocean Biomedical Inc, Sanofi, and Alfasigma SpA

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Malaria (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Malaria (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Malaria (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Malaria (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for Malaria (Infectious Disease)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for Malaria (Infectious Disease).

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding the Malaria (Infectious Disease) pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

60 Degrees Pharmaceuticals LLC
AbbVie Inc
AchilleS Vaccines Srl
Alfasigma SpA
AliquantumRx Inc
Allergy Therapeutics Plc
Altimmune Inc
Artemis Therapeutics Inc
Artificial Cell Technologies Inc
Atomwise Inc
AUM LifeTech Inc
Avalia Immunotherapies Ltd
Bharat Biotech Ltd
BioNTech SE
Blue Water Vaccines Inc
Brain-Gen LLC
Bristol-Myers Squibb Co
Carna Biosciences Inc
Cascade Therapeutics Inc
Cellics Therapeutics Inc
Cesa Alliance SA
Cilian AG
Collaborations Pharmaceuticals Inc
Crystec Ltd
Curevac NV
Curia Inc
Daiichi Sankyo Co Ltd
Eisai Co Ltd
ElSohly Laboratories Inc
EpicentRx Inc
EpiVax Inc
eTheRNA Immunotherapies NV
Evotec SE
Expres2ion Biotechnologies ApS
Exscientia Plc
GeoVax Labs Inc
GSK plc
Hawaii Biotech Inc
Ibex Biosciences LLC
Ichor Medical Systems Inc
IGM Biosciences Inc
Immune Modulation Inc
Imutex Ltd
IMV Inc
Indoco Remedies Ltd
Innovex Therapeutics SL
IPCA Laboratories Ltd
Jacobus Pharmaceutical Co Inc
Johnson & Johnson
Kainomyx Inc
Kymab Ltd
Luckwel Pharmaceuticals Inc
Lumen Bioscience Inc
Lyndra Therapeutics Inc.
MedinCell SA
MediSynergics LLC
MegaNano BioTech Inc
Merck & Co Inc
Merck KGaA
Microbiotix Inc
Mitsubishi Tanabe Pharma Corp
Modus Therapeutics AB
Mycosynthetix Inc
Mymetics Corp
Nobelpharma Co Ltd
Novartis AG
Ocean Biomedical Inc
Osivax SAS
Otsuka Pharmaceutical Co Ltd
Pacific Meniuoke Biopharmaceutical Company
Pfizer Inc
PGTx Ltd
Protein Potential LLC
Replikins Ltd
Rodos BioTarget GmbH
Sanaria Inc
Sanofi
Serum Institute of India Pvt Ltd
Shin Poong Pharm Co Ltd
Shionogi & Co Ltd
Sumaya Biotech GmbH & Co KG
Sumitomo Pharma Co Ltd
Takeda Pharmaceutical Co Ltd
Tandem Nano Ltd
Tarsus Pharmaceuticals Inc
Theravectys SA
UCB SA
Uvax Bio LLC
Vac4All SAS
VicuTec Biologicals GmbH
VLP Biotech Inc
VLP Therapeutics LLC
Zydus Lifesciences Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Malaria – Overview

Malaria – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Malaria – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Malaria – Companies Involved in Therapeutics Development

Malaria – Drug Profiles

Malaria – Dormant Projects

Malaria – Discontinued Products

Malaria – Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Malaria, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Target, 2022 (Contd..1)

Number of Products by Stage and Target, 2022 (Contd..2)

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Malaria – Dormant Projects, 2022

Malaria – Discontinued Products, 2022

Malaria – Discontinued Products, 2022 (Contd..1)

Figures

List of Figures

Number of Products under Development for Malaria, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently asked questions

  • What are the key targets in the Malaria pipeline products market?

    The key targets in the Malaria pipeline products market are Plasmodium falciparum Circumsporozoite Protein, Plasmodium falciparum 25 kDa Ookinete Surface Antigen, Plasmodium falciparum Merozoite Surface Protein 1, P Type ATPase4, Beta Hematin, Dihydroorotate Dehydrogenase (Quinone) Mitochondrial, Heme Polymerase, Plasmodium falciparum Apical Membrane Antigen 1, Plasmodium falciparum Gametocyte Surface Protein P45/48, Plasmodium falciparum Reticulocyte Binding Protein Homologue 5, and others.

  • What are the key mechanisms of action in the Malaria pipeline products market?

    The key mechanisms of action in the Malaria pipeline products market are P Type ATPase4 Inhibitor, Plasmodium falciparum Circumsporozoite Protein Inhibitor, Beta Hematin Inhibitor, Dihydroorotate Dehydrogenase (Quinone) Mitochondrial Inhibitor, Heme Polymerase Inhibitor, 16S Ribosomal RNA Inhibitor, Cytochrome bc1 Complex Inhibitor, Dihydrofolate Reductase Inhibitor, DNA Inhibitor, Histone Lysine N Methyltransferase EHMT2 Inhibitor, and others.

  • What are the key routes of administration in the Malaria pipeline products market?

    The key routes of administration in the Malaria pipeline products market are oral, intramuscular, intravenous, subcutaneous, parenteral, intradermal, inhalational, nasal, and transdermal.

  • What are the key molecule types in the Malaria pipeline products market?

    The key molecule types in the Malaria pipeline products market are small molecule, subunit vaccine, recombinant vector vaccine, vaccine, monoclonal antibody, live attenuated vaccine, mRNA vaccine, DNA vaccine, antisense oligonucleotide, antisense RNAi oligonucleotide, and others.

  • Who are the leading players in the Malaria pipeline products market?

    Some of the leading players in the Malaria pipeline products market are Eisai Co Ltd, GSK plc, Novartis AG, Sanaria Inc, Vac4All SAS, Zydus Lifesciences Ltd, Expres2ion Biotechnologies ApS, Ocean Biomedical Inc, Sanofi, and Alfasigma SpA.

Malaria Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update standard reports
Currency USD
$2,500

Can be used by individual purchaser only

Most Popular
$5,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$7,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Malaria Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Infectious Disease reports
Pharmaceuticals
New
Antibody-Drug Conjugates (ADC) Overview, Industry Trends, Marketed and Pipeline Products,…
$6,995 | March 2024
Pharmaceuticals
New
Cell and Gene Therapies in Ophthalmology - Disease Overview, Treatment…
$6,995 | March 2024
Pharmaceuticals
New
Clinical Trials Scorecard for Investigations in 2023
$695 | March 2024
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Malaria Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Malaria Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more